Posttreatment assessment, significantly correlated with ΔSUV max (p = 0.04) but achieved a slightly significant correlation with deauville criteria (p = 0.055 and p = 0.058). Overall, 1, 3, and 5-year PFS were 95.7 ± 0.2, 89.6 ± 0.4, and 80.8 ± 0.7%, respectively.
Quantitative and visual assessment of IHP can be reliably used at the end of treatment
FDG-PET/(CT) found 27.8% of additional lesions not detected by CT and/or MRI; 29.0% (95% CI: 14.0%–50.5) had a change in FDG-PET(/CT) result or guided treatment %) (I2 = 40.1%).
FDG-PET(/CT) was the most frequently studied imaging modality in patients with PTLD.
The pooled sensitivity of F-18 FDG PET or PET/CT was 0.90, the overall specificity was 0.90, the positive likelihood ratio was 9.4, the negative likelihood ratio was 0.11, and the diagnostic odds ratio was 83.
F-18 FDG PET or PET/CT had high sensitivity and specificity for the detection of PTLD.
